These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19889582)

  • 21. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.
    Tcherepanova I; Harris J; Starr A; Cleveland J; Ketteringham H; Calderhead D; Horvatinovich J; Healey D; Nicolette CA
    PLoS One; 2008 Jan; 3(1):e1489. PubMed ID: 18231576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo targeting of protein antigens to dendritic cells using anti-DEC-205 single chain antibody improves HIV Gag specific CD4
    Ngu LN; Nji NN; Ambada GE; Sagnia B; Sake CN; Tchadji JC; Njambe Priso GD; Lissom A; Tchouangueu TF; Manga Tebit D; Waffo AB; Park CG; Steinman RM; Überla K; Nchinda GW
    Immun Inflamm Dis; 2019 Jun; 7(2):55-67. PubMed ID: 28474788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Killing of Latently HIV-Infected CD4 T Cells by Autologous CD8 T Cells Is Modulated by Nef.
    Sevilya Z; Chorin E; Gal-Garber O; Zelinger E; Turner D; Avidor B; Berke G; Hassin D
    Front Immunol; 2018; 9():2068. PubMed ID: 30254642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expansion ability but not the quality of HIV-specific CD8(+) T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors.
    López M; Peris A; Soriano V; Lozano S; Vicario JL; Rallón NI; Restrepo C; Benito JM
    Immunology; 2011 Nov; 134(3):305-13. PubMed ID: 21978000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Specific immune responses to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins].
    Zhai S; Kang WZ; Yu X; Wang SY; Walker BD; Altfeld M; Sun YT
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):175-9. PubMed ID: 15766402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants.
    Thobakgale CF; Ramduth D; Reddy S; Mkhwanazi N; de Pierres C; Moodley E; Mphatswe W; Blanckenberg N; Cengimbo A; Prendergast A; Tudor-Williams G; Dong K; Jeena P; Kindra G; Bobat R; Coovadia H; Kiepiela P; Walker BD; Goulder PJ
    J Virol; 2007 Dec; 81(23):12775-84. PubMed ID: 17881456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of Gag- and Env-Specific CD8+ T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy.
    Prebensen C; Lind A; Dyrhol-Riise AM; Kvale D
    PLoS One; 2016; 11(4):e0153849. PubMed ID: 27128502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.
    Allard SD; De Keersmaecker B; de Goede AL; Verschuren EJ; Koetsveld J; Reedijk ML; Wylock C; De Bel AV; Vandeloo J; Pistoor F; Heirman C; Beyer WE; Eilers PH; Corthals J; Padmos I; Thielemans K; Osterhaus AD; Lacor P; van der Ende ME; Aerts JL; van Baalen CA; Gruters RA
    Clin Immunol; 2012 Mar; 142(3):252-68. PubMed ID: 22177848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.
    Ananworanich J; Puthanakit T; Suntarattiwong P; Chokephaibulkit K; Kerr SJ; Fromentin R; Bakeman W; Intasan J; Mahanontharit A; Sirivichayakul S; Chomont N;
    AIDS; 2014 Apr; 28(7):1015-20. PubMed ID: 24384692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection.
    Eller MA; Eller LA; Ratto-Kim S; Ouma BJ; Lo V; de Souza M; Guwatudde D; Nails B; Michael NL; Wabwire-Mangen F; Robb ML; Marovich MA; Sandberg JK; Currier JR
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):9-18. PubMed ID: 22580564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.
    Omondi FH; Chandrarathna S; Mujib S; Brumme CJ; Jin SW; Sudderuddin H; Miller RL; Rahimi A; Laeyendecker O; Bonner P; Yue FY; Benko E; Kovacs CM; Brockman MA; Ostrowski M; Brumme ZL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.
    Miller E; Spadaccia M; Sabado R; Chertova E; Bess J; Trubey CM; Holman RM; Salazar A; Lifson J; Bhardwaj N
    Vaccine; 2015 Jan; 33(2):388-95. PubMed ID: 25444812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.
    Betts MR; Ambrozak DR; Douek DC; Bonhoeffer S; Brenchley JM; Casazza JP; Koup RA; Picker LJ
    J Virol; 2001 Dec; 75(24):11983-91. PubMed ID: 11711588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pregnancy Gestation Impacts on HIV-1-Specific Granzyme B Response and Central Memory CD4 T Cells.
    Cocker ATH; Shah NM; Raj I; Dermont S; Khan W; Mandalia S; Imami N; Johnson MR
    Front Immunol; 2020; 11():153. PubMed ID: 32117291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral therapy-induced dominant interleukin-2 HIV-1 Gag CD4+ T cell response: evidence of functional recovery of HIV-1-specific CD4+ T cells.
    Tsalimalma K; Kordossis T; Choremi-Papadopoulou E
    Scand J Immunol; 2011 Mar; 73(3):256-65. PubMed ID: 21204901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.